 |
Maryland Oncology Hematology expands services in northwestern Maryland with addition of two board-certified physicians and two locationsJuly 25, 2011 |
|
|
|
|
Maryland Oncology Hematology, P.A. (MOH) announced today that through the addition of two locations and two board-certified physicians, it is expanding the suite of oncology services it provides. Columbia, Md. (July 25, 2011) — Maryland Oncology Hematology, P.A. (MOH), an affiliate of The US Oncology Network, announced today that through the addition of two locations and two board-certified physicians, it is expanding the suite of oncology services it provides. The oncology practice has now expanded from 11 physicians to 13 and from four locations to six. 
"The addition of more locations and two highly-qualified oncologists to our practice allows us to care for cancer patients throughout the state of Maryland and parts of Pennsylvania and Washington, D.C.," said Nicholas Koutrelakos, M.D., hematologist and oncologist, MOH. "Being able to give more patients access to integrated, evidence-based cancer care and clinical research is extremely important to us at Maryland Oncology Hematology." Maryland Oncology Hematology welcomes Drs. Robert Rice and Mohit Narang. They will work alongside other board-certified physicians to treat patients in Gettysburg, Pennsylvania and in Owings Mills, Columbia, Greenbelt, Laurel, and Silver Spring, Maryland. Dr. Rice received his Medical Doctorate from the University of Pittsburgh School of Medicine. He completed his residency in internal medicine at University Hospitals Case Medical Center in Cleveland and then completed a fellowship in Hematology/Oncology at Vanderbilt University Medical Center. In addition to being published several times, Dr. Rice was the recipient of multiple awards including the American Associates of Cancer Research Young Investigator Award. "I'm excited to join such a compassionate staff," said Robert Rice, M.D., Ph.D., hematologist and oncologist, MOH. "I'm looking forward to working together to give cancer patients the high-quality care they need and deserve." Dr. Narang completed his Hematology/Oncology fellowship at Michigan State University in Lansing, MI. He received his M.B., B.S. at Dayanand Medical College in Ludhiana, India and completed his Internal Medicine Residency at Christ Hospital in Cincinnati, Ohio. As an active participant in the medical community, Dr. Narang has served as a primary investigator and research assistant on many trials. "Being able to provide patients top-notch care as well as an opportunity to participate in innovative clinical trials in the community setting close to home are top priorities at Maryland Oncology Hematology," said Mohit Narang, M.D., oncologist, MOH. "The staff at Maryland Oncology Hematology is dedicated to this mission, and I'm proud to be a part of it." As part of the US Oncology Research network, Maryland Oncology Hematology provides patients with an increased opportunity to participate in innovative clinical trials and access to the latest treatment options without having to travel miles away from home. US Oncology Research network physicians have played a pivotal role in the development of 43 cancer-fighting therapies approved by the FDA and helped more than 48,000 patients participate in clinical trials. As a member of The US Oncology Network, the physicians of Maryland Hematology Oncology are able to collaborate with more than 1,100 oncologists and leading researchers from around the country to offer improved therapeutic drug management programs, cutting-edge clinical trials and an established evidence-based medicine approach to delivering patient care. About Maryland Oncology Hematology Maryland Oncology Hematology is united in healing with The US Oncology Network, one of the nation’s largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, MOH is united with more than 1,100 physicians and 10,000 cancer professionals nationwide. Through the US Oncology Research network, Maryland Oncology Hematology participates in clinical trials and has helped to develop 43 FDA approved cancer therapies. For more information, visit www.usoncology.com.
Media Contacts:Claire Crye, The US Oncology Network Mary Beth Zaber, Maryland Oncology Hematology |
||||
